On November 13, 2025, OncoLab took part in the “2025 KPBMA Open Innovation Plaza” at EL Tower in Seoul as an invited speaker in the technology trend session. Organized by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), the event brought together pharmaceutical and biotech companies, investors, and researchers to discuss R&D pipelines and open-innovation strategies across the industry.

During the morning session, CEO Jongseong Kim delivered a presentation titled “ANGel beyond Immunotherapy,” outlining a precision drug-delivery strategy that targets the tumor microenvironment and aims to overcome current limitations of immuno-oncology. The talk emphasized a shift away from conventional systemic administration toward localized, peritumoral delivery, with more controlled exposure at the injection site to improve both safety and efficacy.